Detalhe da pesquisa
1.
Cost-Effectiveness of Sacubitril/Valsartan in Germany: An Application of the Efficiency Frontier.
Value Health
; 22(10): 1119-1127, 2019 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-31563254
2.
An Economic Evaluation of Sacubitril/Valsartan for Heart Failure Patients in the Netherlands.
Value Health
; 20(3): 388-396, 2017 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-28292483
3.
A New Statistical Method to Determine the Degree of Validity of Health Economic Model Outcomes against Empirical Data.
Value Health
; 20(8): 1041-1047, 2017 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-28964435
4.
Higher Adherence During Reimbursement of Pharmacological Smoking Cessation Treatments.
Nicotine Tob Res
; 18(1): 56-63, 2016 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-25782457
5.
Author's Reply.
Value Health
; 23(5): 675-676, 2020 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-32389235
6.
Economics of chronic diseases protocol: cost-effectiveness modelling and the future burden of non-communicable disease in Europe.
BMC Public Health
; 14: 456, 2014 May 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-24886110
7.
Crossing borders: factors affecting differences in cost-effectiveness of smoking cessation interventions between European countries.
Value Health
; 13(2): 230-41, 2010.
Artigo
em Inglês
| MEDLINE | ID: mdl-19804435
8.
The risk of overestimating cost savings from hospital-at-home schemes: A literature review.
Int J Nurs Stud
; 109: 103652, 2020 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-32569827
9.
Costs of clinical events in type 2 diabetes mellitus patients in the Netherlands: A systematic review.
PLoS One
; 14(9): e0221856, 2019.
Artigo
em Inglês
| MEDLINE | ID: mdl-31490989
10.
Improving model validation in health technology assessment: comments on guidelines of the ISPOR-SMDM modeling good research practices task force.
Value Health
; 16(6): 1106-7, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-24041364
11.
Research Costs Investigated: A Study Into the Budgets of Dutch Publicly Funded Drug-Related Research.
Pharmacoeconomics
; 36(1): 105-113, 2018 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28933003
12.
Mix and match. A simulation study on the impact of mixed-treatment comparison methods on health-economic outcomes.
PLoS One
; 12(2): e0171292, 2017.
Artigo
em Inglês
| MEDLINE | ID: mdl-28152099
13.
Economic Burden in Chinese Patients with Diabetes Mellitus Using Electronic Insurance Claims Data.
PLoS One
; 11(8): e0159297, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-27570976
14.
Unremarked or Unperformed? Systematic Review on Reporting of Validation Efforts of Health Economic Decision Models in Seasonal Influenza and Early Breast Cancer.
Pharmacoeconomics
; 34(9): 833-45, 2016 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-27129572
15.
The Missing Stakeholder Group: Why Patients Should be Involved in Health Economic Modelling.
Appl Health Econ Health Policy
; 14(2): 129-33, 2016 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-26385585
16.
Cost-Analysis of Seven Nosocomial Outbreaks in an Academic Hospital.
PLoS One
; 11(2): e0149226, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26863145
17.
Cost-effectiveness of obinutuzumab for chronic lymphocytic leukaemia in The Netherlands.
Leuk Res
; 50: 37-45, 2016 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-27657652
18.
Financial evaluations of antibiotic stewardship programs-a systematic review.
Front Microbiol
; 6: 317, 2015.
Artigo
em Inglês
| MEDLINE | ID: mdl-25932024
19.
A few years later. Update of the cost-effectiveness of infant pneumococcal vaccination in Dutch children.
Hum Vaccin Immunother
; 10(7): 1841-9, 2014.
Artigo
em Inglês
| MEDLINE | ID: mdl-25424791
20.
Not simply more of the same: distinguishing between patient heterogeneity and parameter uncertainty.
Med Decis Making
; 34(8): 1048-58, 2014 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-25216723